Q-omics provides the consensus-scored RXFP3 profile across patient tissues and cancer cell-line models. RXFP3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RXFP3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RXFP3 RNA expression shows 11,813 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight ACC, HNSC, and PCPG as cancer lineages where RXFP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RXFP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RXFP3 survival associations across molecular data types. RXFP3 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RXFP3 RNA expression–survival associations across cancer types. High RXFP3 expression shows unfavorable associations in ACC, DLBC, SKCM, MESO and COAD, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for RXFP3 RNA expression.
This table summarizes RXFP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RXFP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RXFP3 shows higher tumor expression in HNSC, COAD, BRCA, BLCA, LUSC and STAD. The HNSC box plot shows higher RXFP3 RNA expression in tumor versus normal tissue (log2 FC = +0.107, t-test p < 0.001).
This table shows molecular features associated with RXFP3 in patient tissues and cancer cell lines. In patient samples, RXFP3 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, RXFP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
